IMMX earnings date and last-quarter result: next report 2026-08-14, last quarter beat, P/E -10.23. Updated 2026-07-23.
Immix Biopharma (IMMX) Research Hub
Immix Biopharma (IMMX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 8.06 USD (-1.10%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.23, market cap 0.51B. This hub links to the full technical, earnings and options research available for IMMX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.06 USD (-1.10%) |
| 52-week range | 7.88 USD – 15.1 USD |
| Trend regime | Range |
| 14-day RSI | 30.8 (Bearish) |
| Trailing P/E | -10.23 |
| Market cap | 0.51B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for IMMX
Covered Call on IMMX: how it works, illustrative setup around the real 8.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IMMX: how it works, illustrative setup around the real 8.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IMMX: how it works, illustrative setup around the real 8.06 USD price, max profit/loss, breakeven and when to use it. Educational.
IMMX technical analysis: range, last 8.06 USD, RSI 30.8, 52w range 7.88 USD–15.1 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is IMMX in?
Immix Biopharma (IMMX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IMMX in an uptrend or downtrend?
As of 2026-10-26, IMMX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IMMX's trailing P/E ratio?
IMMX's trailing P/E is -10.23, with a market cap of 0.51B. See the earnings research page for full valuation detail.
When does IMMX next report earnings?
IMMX is next scheduled to report earnings on 2026-08-14.